The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

As we are approaching winter and there is an increase in respiratory diseases, it’s also important to know about pneumococcal ...